- Products & Services
- Knowledge Base
PHILADELPHIA, PA, September 23, 2022 /24-7PressRelease/ -- Somatolink Foundation, Inc. a US (Delaware) incorporated Public Benefit Corporation research organization, with a stated public benefit and goal to provide affordable, equitable genomic services and therapies, announces their registration in the state of Pennsylvania. Somatolink is developing targeted therapies in oncology and psoriasis based on solid research, biomarker discovery and personalized genomics while using a novel operational model centered on the patient as key stakeholder. Our current pipeline includes defined biotargets for a variety of solid neoplasms applicable to psoriasis. In addition, our business model integrates a personalized genomics/diagnostic platform with an expert patient to patient network (EPFP) design, in general partnership with the ISOPROG-Somatolink EPFP Research Network, to 'put the patient first'.
Somatolink Foundation, Inc. a Delaware Public Benefit Corporation, is a research-biotech organization, with a public benefit and goal to provide affordable, equitable genomic services and newly developed therapeutics, in the areas of cancer and psoriasis, by leveraging an Expert-for-Patient-Research Network (the ISOPROG-Somatolink EPFP Research Network). This public benefit is realized by a unique operational model of personalized medicine, which puts the patient's bioassets at the center of their healthcare. Together with a portfolio of unique biotargets in solid cancers and psoriasis, Somatolink, in conjunction with ISOPROG is building out an organizational and computational framework to manage and research a patient's bioassets from biobanking through personalized drug discovery.
# # #